Compare CALX & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALX | IRON |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.0B |
| IPO Year | 2009 | 2020 |
| Metric | CALX | IRON |
|---|---|---|
| Price | $53.20 | $66.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $74.75 | ★ $99.54 |
| AVG Volume (30 Days) | ★ 1.3M | 943.0K |
| Earning Date | 04-29-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.78 | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $510,367,000.00 | N/A |
| Revenue This Year | $16.40 | N/A |
| Revenue Next Year | $13.75 | $215.03 |
| P/E Ratio | $198.21 | ★ N/A |
| Revenue Growth | ★ 11.24 | N/A |
| 52 Week Low | $28.61 | $30.82 |
| 52 Week High | $71.22 | $99.50 |
| Indicator | CALX | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 51.13 | 43.58 |
| Support Level | $51.66 | $57.45 |
| Resistance Level | $56.17 | $82.70 |
| Average True Range (ATR) | 2.62 | 6.10 |
| MACD | 0.00 | 0.27 |
| Stochastic Oscillator | 47.83 | 73.52 |
Calix Inc develops, markets and sells its appliance-based platform, cloud and managed services that enable service providers of all types and sizes to innovate and transform their businesses. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Middle East & Africa, Europe, Asia Pacific and other markets.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.